Answers are grounded in this paper and cite their sources.
Review of dynamic biomarkers guiding therapy in hormone receptor-positive breast cancer, highlighting a shift towards proactive oncology.
Hormone receptor-positive/HER2-negative breast cancer evolves in response to therapy, demanding smarter, adaptive biomarker-based treatment strategies. We review emerging dynamic biomarkers to guide therapeutic decision-making, spanning tissue and liquid biopsies, metabolic imaging, and microbiome profiling, that capture tumor or host-related changes over time. By contrasting Academic and Industry approaches, we advocate for a cultural shift in clinical trial design and implementation, aiming to move from reactive to proactive Oncology.
No takes yet. Share an insight, caveat, or question.
Grazia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: